Katora

Sildenafil citrate, the active ingredient in Katora, is a phosphodiesterase type 5 (PDE5) inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of erectile dysfunction and for pulmonary arterial hypertension in adult patients. It is marketed within the European Union and requires a prescription.

GNH USA supplies Katora as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across multiple markets, and is distributed through authorized channels.

Sildenafil citrate acts on the nitric‑oxide/cGMP pathway to improve vascular smooth‑muscle relaxation in specific conditions.

- Erectile dysfunction: enhances ability to achieve and maintain an erection sufficient for sexual activity. - Pulmonary arterial hypertension: lowers pulmonary arterial pressure and improves exercise capacity in affected patients.

Sildenafil citrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Flushing - Dyspepsia - Nasal congestion - Visual disturbances (e.g., blurred vision)

Serious or Rare Side Effects: - Priapism (prolonged erection) - Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy) - Sudden loss of hearing - Cardiovascular events such as myocardial infarction or stroke

Before prescribing sildenafil citrate, clinicians should consider several safety factors.

- Cardiovascular assessment: evaluate patients with underlying heart disease before use. - Nitrate therapy: contraindicated with nitrates or nitric‑oxide donors. - Blood pressure: use caution in uncontrolled hypertension or hypotension. - Renal/hepatic impairment: dose adjustment may be required in severe impairment. - Visual disorders: avoid in patients with retinitis pigmentosa or other retinal diseases. - Store at below 25°C: keep in the original pack, protect from moisture.

Sildenafil citrate can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Nitrates (including nitroglycerin): concurrent use can cause severe hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase sildenafil exposure.

Moderate Interactions (Monitor Closely): - Alpha‑blockers: may enhance blood‑pressure‑lowering effects. - Antihypertensive agents: additive hypotensive effect possible. - CYP3A4 inducers (e.g., rifampin): may reduce sildenafil effectiveness.